PMC9981998_01
The clinical course along with schematic diagram of possible genetic backgrounds of the series of hematological malignancies The R-CHOP therapy might introduce genetic alterations, such as KMT2A translocation in progenitor cells, from which CMMoL and APLL were derived. In addition, acquiring genetic mutation in NRAS resulted in leukemic translation. R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; Aza, azacitidine; DLBCL, diffuse large B-cell lymphoma; CMMoL, chronic myelomonocytic leukemia; APLL, acute promyelocytic-like leukemia; PR, partial response; GMP, granulocyte/monocyte progenitors.
fonc-13-1116418-g001.jpg
PMC9981998_01_fonc-13-1116418-g001.jpg
f1
See the supplemental information for more detailed clinical course and supporting findings ( Figures S1 - S8 ). Overview of the clinical course of this patient, along with the possible genetic backgrounds of the series of hematological malignancies, is presented in  Figure 1 .
Translocation between KMT2A and ACTN4 genes. It was commonly detected in the CMMoL and APLL samples.
fonc-13-1116418-g002.jpg
PMC9981998_01_fonc-13-1116418-g002.jpg
f2
See the supplemental information for more detailed clinical course and supporting findings ( Figures S1 - S8 ). Notably, WGS analysis was able to detect a chromosomal translocation involving 11q23.3 (KMT2A) and 19q13.2 (ACTN4) loci, both in CMMoL and APLL samples ( Figure 2  and  Table S3 ); this is the only SV that was detected commonly in CMMoL and APLL samples.